Skip to main content

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Gastrointestinal Cancer Specialty Channel

Gastrointestinal Cancer
Specialty Channel
News
05/23/2024

Stephanie Holland 

Stephanie Holland 
According to results from the phase 2 RELATIVITY-060 study, the addition of relatlimab to nivolumab and chemotherapy did not improve objective response among patients with unresectable, locally advanced or metastatic gastric or...
According to results from the phase 2 RELATIVITY-060 study, the addition of relatlimab to nivolumab and chemotherapy did not improve objective response among patients with unresectable, locally advanced or metastatic gastric or...
According to results from the...
05/23/2024
Oncology
News
04/24/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the NETTER-P and NETTER-1 studies, the FDA has approved lutetium Lu 177 dotatate for pediatric patients aged 12 and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.
Based on results from the NETTER-P and NETTER-1 studies, the FDA has approved lutetium Lu 177 dotatate for pediatric patients aged 12 and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.
Based on results from the...
04/24/2024
Oncology
News
04/08/2024

Stephanie Holland 

Stephanie Holland 
The FDA granted accelerated approval to trastuzumab deruxtecan for patients with unresectable or metastatic HER2-positive solid tumors who have received systemic treatment and have no alternative treatment options.
The FDA granted accelerated approval to trastuzumab deruxtecan for patients with unresectable or metastatic HER2-positive solid tumors who have received systemic treatment and have no alternative treatment options.
The FDA granted accelerated...
04/08/2024
Oncology
Conference Coverage
01/19/2024

Stephanie Holland 

Stephanie Holland 
According to primary analysis results from the phase 3 NETTER-2 study, first-line [177Lu] Lu-DOTA-TATE significantly prolonged PFS and demonstrated a clinically meaningful ORR among patients with newly diagnosed, advanced grade 2 and 3...
According to primary analysis results from the phase 3 NETTER-2 study, first-line [177Lu] Lu-DOTA-TATE significantly prolonged PFS and demonstrated a clinically meaningful ORR among patients with newly diagnosed, advanced grade 2 and 3...
According to primary analysis...
01/19/2024
Oncology
Conference Coverage
01/19/2024

Janelle Bradley

Janelle Bradley
First-line treatment with atezolizumab and bevacizumab plus chemotherapy provides PFS advantage vs atezolizumab plus placebo and chemotherapy for patients with advanced biliary tract cancer, according to findings from the phase 2 IMbrave151...
First-line treatment with atezolizumab and bevacizumab plus chemotherapy provides PFS advantage vs atezolizumab plus placebo and chemotherapy for patients with advanced biliary tract cancer, according to findings from the phase 2 IMbrave151...
First-line treatment with...
01/19/2024
Oncology
Conference Coverage
01/18/2024
Allison Casey
According to results from the phase 3 SKYSCRAPER-08, tiragolumab plus atezolizumab and chemotherapy improved the progression-free survival and overall survival among patients with esophageal squamous cell carcinoma.
According to results from the phase 3 SKYSCRAPER-08, tiragolumab plus atezolizumab and chemotherapy improved the progression-free survival and overall survival among patients with esophageal squamous cell carcinoma.
According to results from the...
01/18/2024
Oncology
News
10/16/2023

Allison Casey

Allison Casey
In a phase 3 clinical trial, thrombosis rates of patients with gastrointestinal and lung cancer with high-risk profiles were mitigated to those comparable to the rates of patients with low-risk profiles with a risk-directed primary...
In a phase 3 clinical trial, thrombosis rates of patients with gastrointestinal and lung cancer with high-risk profiles were mitigated to those comparable to the rates of patients with low-risk profiles with a risk-directed primary...
In a phase 3 clinical trial,...
10/16/2023
Oncology
News
10/13/2023

Allison Casey 

Allison Casey 
According to results from a phase 2 basket study, tucatinib plus trastuzumab demonstrated antitumor activity and was well-tolerated among patients with previously treated HER2-positive metastatic biliary tract cancer.
According to results from a phase 2 basket study, tucatinib plus trastuzumab demonstrated antitumor activity and was well-tolerated among patients with previously treated HER2-positive metastatic biliary tract cancer.
According to results from a...
10/13/2023
Oncology
Zev Wainberg, MD, UCLA
Videos
08/22/2023

Featuring Zev Wainberg, MD 

Featuring Zev Wainberg, MD 
At the 2023 World Congress on Gastrointestinal Cancers, Zev Wainberg, MD, presented results from the final analysis of the phase 2 FIGHT trial.
At the 2023 World Congress on Gastrointestinal Cancers, Zev Wainberg, MD, presented results from the final analysis of the phase 2 FIGHT trial.
At the 2023 World Congress on...
08/22/2023
Oncology
Patrick Tan, MD, PhD, Genome Institute of Singapore
Videos
08/22/2023

Featuring Patrick Tan, MD, PhD

Featuring Patrick Tan, MD, PhD ...
At the 2023 World Congress on Gastrointestinal Cancers, Patrick Tan, MD, PhD, presented a keynote lecture on new strategies to achieve molecular classification in gastric cancer that can potentially inform the future treatment landscape.
At the 2023 World Congress on Gastrointestinal Cancers, Patrick Tan, MD, PhD, presented a keynote lecture on new strategies to achieve molecular classification in gastric cancer that can potentially inform the future treatment landscape.
At the 2023 World Congress on...
08/22/2023
Oncology
Antonella Cammarota, MD, Humanitas University
Videos
08/21/2023

Featuring Antonella Cammarota, MD 

Featuring Antonella Cammarota, MD  ...
At the 2023 World Congress on Gastrointestinal Cancers, Antonella Cammarota, MD, presented results from a study relating prior chemotherapy administration with heterogeneity of CLDN18.2 among patients with resectable gastroesophageal cancers.
At the 2023 World Congress on Gastrointestinal Cancers, Antonella Cammarota, MD, presented results from a study relating prior chemotherapy administration with heterogeneity of CLDN18.2 among patients with resectable gastroesophageal cancers.
At the 2023 World Congress on...
08/21/2023
Oncology

Advertisement

News

News
05/23/2024

Stephanie Holland 

Stephanie Holland 
According to results from the phase 2 RELATIVITY-060 study, the addition of relatlimab to nivolumab and chemotherapy did not improve objective response among patients with unresectable, locally advanced or metastatic gastric or...
According to results from the phase 2 RELATIVITY-060 study, the addition of relatlimab to nivolumab and chemotherapy did not improve objective response among patients with unresectable, locally advanced or metastatic gastric or...
According to results from the...
05/23/2024
Oncology
News
04/24/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the NETTER-P and NETTER-1 studies, the FDA has approved lutetium Lu 177 dotatate for pediatric patients aged 12 and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.
Based on results from the NETTER-P and NETTER-1 studies, the FDA has approved lutetium Lu 177 dotatate for pediatric patients aged 12 and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.
Based on results from the...
04/24/2024
Oncology
News
04/08/2024

Stephanie Holland 

Stephanie Holland 
The FDA granted accelerated approval to trastuzumab deruxtecan for patients with unresectable or metastatic HER2-positive solid tumors who have received systemic treatment and have no alternative treatment options.
The FDA granted accelerated approval to trastuzumab deruxtecan for patients with unresectable or metastatic HER2-positive solid tumors who have received systemic treatment and have no alternative treatment options.
The FDA granted accelerated...
04/08/2024
Oncology
Conference Coverage
01/19/2024

Stephanie Holland 

Stephanie Holland 
According to primary analysis results from the phase 3 NETTER-2 study, first-line [177Lu] Lu-DOTA-TATE significantly prolonged PFS and demonstrated a clinically meaningful ORR among patients with newly diagnosed, advanced grade 2 and 3...
According to primary analysis results from the phase 3 NETTER-2 study, first-line [177Lu] Lu-DOTA-TATE significantly prolonged PFS and demonstrated a clinically meaningful ORR among patients with newly diagnosed, advanced grade 2 and 3...
According to primary analysis...
01/19/2024
Oncology
Conference Coverage
01/19/2024

Janelle Bradley

Janelle Bradley
First-line treatment with atezolizumab and bevacizumab plus chemotherapy provides PFS advantage vs atezolizumab plus placebo and chemotherapy for patients with advanced biliary tract cancer, according to findings from the phase 2 IMbrave151...
First-line treatment with atezolizumab and bevacizumab plus chemotherapy provides PFS advantage vs atezolizumab plus placebo and chemotherapy for patients with advanced biliary tract cancer, according to findings from the phase 2 IMbrave151...
First-line treatment with...
01/19/2024
Oncology
Conference Coverage
01/18/2024
Allison Casey
According to results from the phase 3 SKYSCRAPER-08, tiragolumab plus atezolizumab and chemotherapy improved the progression-free survival and overall survival among patients with esophageal squamous cell carcinoma.
According to results from the phase 3 SKYSCRAPER-08, tiragolumab plus atezolizumab and chemotherapy improved the progression-free survival and overall survival among patients with esophageal squamous cell carcinoma.
According to results from the...
01/18/2024
Oncology
News
10/16/2023

Allison Casey

Allison Casey
In a phase 3 clinical trial, thrombosis rates of patients with gastrointestinal and lung cancer with high-risk profiles were mitigated to those comparable to the rates of patients with low-risk profiles with a risk-directed primary...
In a phase 3 clinical trial, thrombosis rates of patients with gastrointestinal and lung cancer with high-risk profiles were mitigated to those comparable to the rates of patients with low-risk profiles with a risk-directed primary...
In a phase 3 clinical trial,...
10/16/2023
Oncology
News
10/13/2023

Allison Casey 

Allison Casey 
According to results from a phase 2 basket study, tucatinib plus trastuzumab demonstrated antitumor activity and was well-tolerated among patients with previously treated HER2-positive metastatic biliary tract cancer.
According to results from a phase 2 basket study, tucatinib plus trastuzumab demonstrated antitumor activity and was well-tolerated among patients with previously treated HER2-positive metastatic biliary tract cancer.
According to results from a...
10/13/2023
Oncology
Zev Wainberg, MD, UCLA
Videos
08/22/2023

Featuring Zev Wainberg, MD 

Featuring Zev Wainberg, MD 
At the 2023 World Congress on Gastrointestinal Cancers, Zev Wainberg, MD, presented results from the final analysis of the phase 2 FIGHT trial.
At the 2023 World Congress on Gastrointestinal Cancers, Zev Wainberg, MD, presented results from the final analysis of the phase 2 FIGHT trial.
At the 2023 World Congress on...
08/22/2023
Oncology
Patrick Tan, MD, PhD, Genome Institute of Singapore
Videos
08/22/2023

Featuring Patrick Tan, MD, PhD

Featuring Patrick Tan, MD, PhD ...
At the 2023 World Congress on Gastrointestinal Cancers, Patrick Tan, MD, PhD, presented a keynote lecture on new strategies to achieve molecular classification in gastric cancer that can potentially inform the future treatment landscape.
At the 2023 World Congress on Gastrointestinal Cancers, Patrick Tan, MD, PhD, presented a keynote lecture on new strategies to achieve molecular classification in gastric cancer that can potentially inform the future treatment landscape.
At the 2023 World Congress on...
08/22/2023
Oncology

Interactive Features

Quiz
10/17/2022
Do you know which chemotherapy regimen was found to be the standard first-line option for patients with advanced neuroendocrine carcinomas of the digestive system?
Do you know which chemotherapy regimen was found to be the standard first-line option for patients with advanced neuroendocrine carcinomas of the digestive system?
Do you know which chemotherapy...
10/17/2022
Oncology
Test Your Knowledge
09/08/2021
Which of the following uncommon cancers are classified as biliary tract cancers?
Which of the following uncommon cancers are classified as biliary tract cancers?
Which of the following uncommon...
09/08/2021
Oncology
Quiz
08/09/2021
True or false: The combination of atorvastatin and metformin have been shown to reduce the progression of chronic active hepatitis and cirrhosis to hepatocellular carcinoma, as well as increase the power of sorafenib, and develops a direct...
True or false: The combination of atorvastatin and metformin have been shown to reduce the progression of chronic active hepatitis and cirrhosis to hepatocellular carcinoma, as well as increase the power of sorafenib, and develops a direct...
True or false: The combination...
08/09/2021
Oncology
Test Your Knowledge
01/28/2021
True or false: Anlotinib has shown benefit in Chinese patients with refractory metastatic RAS/KRAS/BRAF-wildtype colorectal cancer.
True or false: Anlotinib has shown benefit in Chinese patients with refractory metastatic RAS/KRAS/BRAF-wildtype colorectal cancer.
True or false: Anlotinib has...
01/28/2021
Oncology
Test Your Knowledge
08/28/2020
True or false: Infigratinib did not yield a survival benefit in patients with cholangiocarcinoma and FGFR2 fusions.
True or false: Infigratinib did not yield a survival benefit in patients with cholangiocarcinoma and FGFR2 fusions.
True or false: Infigratinib did...
08/28/2020
Oncology
Test Your Knowledge
08/21/2020
True or false: In patients with unresectable PDGFRA D842V-Mutant GIST, avapritinib did not demonstrate meaningful activity.
True or false: In patients with unresectable PDGFRA D842V-Mutant GIST, avapritinib did not demonstrate meaningful activity.
True or false: In patients with...
08/21/2020
Oncology
Test Your Knowledge
08/21/2020
True or false: Classifying and differentiating tumor tissue from pure fibrosis during surgery for CRC is possible.
True or false: Classifying and differentiating tumor tissue from pure fibrosis during surgery for CRC is possible.
True or false: Classifying and...
08/21/2020
Oncology
Test Your Knowledge
07/31/2020
True or false: Overall survival disparity exists between the use of oxaliplatin and mitomycin C during CRS-HIPEC for colorectal peritoneal metastases.
True or false: Overall survival disparity exists between the use of oxaliplatin and mitomycin C during CRS-HIPEC for colorectal peritoneal metastases.
True or false: Overall survival...
07/31/2020
Oncology
Test Your Knowledge
06/22/2020
True or False: MDMs in plasma show promise as a method for accurately detecting distant recurrent CRC.
True or False: MDMs in plasma show promise as a method for accurately detecting distant recurrent CRC.
True or False: MDMs in plasma...
06/22/2020
Oncology
Test Your Knowledge
06/04/2020
True or False: Pembrolizumab should be the new standard of care for MSI-H/dMMR metastatic colorectal cancer?
True or False: Pembrolizumab should be the new standard of care for MSI-H/dMMR metastatic colorectal cancer?
True or False: Pembrolizumab...
06/04/2020
Oncology

Advertisement

Advertisement

Advertisement

Advertisement